Avalon GloboCare launches KetoAir breathalyzer in the US
- Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
- 04/23/2024
|
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
- FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.
- 04/22/2024
|
Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer
- Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union. Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.
- 03/28/2024
|
Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union
- FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.
- 03/28/2024
|
Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU). The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.
- 12/18/2023
|
Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US
- FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU).
- 12/18/2023
|
Avalon GloboCare partners with Qi Diagnostics on clinical studies of DKAir breathalyzer for diabetic ketoacidosis
- Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA). Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.
- 10/18/2023
|
Avalon GloboCare debuts KetoAir app on Apple App Store
- Avalon GloboCare Corp (NASDAQ:ALBT) has officially unveiled its KetoAir mobile application on the Apple App Store. Coupled with an AI nutritionist and a nanosensor-based breathalyzer, KetoAir serves as a companion diagnostic and monitoring device for individuals practicing a ketogenic lifestyle The app, designed to facilitate ketogenic dietary management, is now also available for download on the Google Play store.
- 10/04/2023
|
Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application
- KetoAir™ Mobile Application Launches in Apple App Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store.
- 10/04/2023
|
Avalon GloboCare shares spike on Laboratory Services MSO acquisitions
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned clinical diagnostics and reference lab Laboratory Services MSO (LSM) has made two significant accretive acquisitions: Merlin Medical Supply (MMS) and Leading Edge Innovations. MMS is a home medical equipment and durable medical equipment company operating in Ventura County, California, which has contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health and Gold Coast.
- 09/13/2023
|
Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device
- FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. Avalon owns a 40% interest in LSM.
- 09/13/2023
|
Avalon GloboCare shares surge as recent momentum continues
- Avalon GloboCare Corp (NASDAQ:ALBT) shares climbed 29% to $1.24 on Tuesday after the precision diagnostics and clinical laboratory services provider said it received a new US patent titled "QTY Fc Fusion Water Soluble Receptor Proteins," a collaborative effort with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT), which encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code." According to the company, the QTY Code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.
- 09/05/2023
|
Avalon GloboCare adds QTY Code patent to its portfolio
- Avalon GloboCare Corp (NASDAQ:ALBT) has received a new patent to add to its portfolio. The Freehold, New Jersey-based company announced the United States Patent and Trademark Office (USPTO) issued a Notice of Publication for U.S.
- 09/05/2023
|
Avalon GloboCare investee LSM launches innovative lab test for tuberculosis
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned Laboratory Services MSO, LLC (LSM) is now offering an in-house laboratory developed test (LDT) to detect tuberculosis (TB) using a patient's sputum sample. The developer of innovative cell-based technology, cellular therapy and precision diagnostics said the new test method is expected to generate revenue in 2023.
- 08/30/2023
|
Avalon's Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis
- New Proprietary Testing Method Makes Tuberculosis Diagnosis Easier and Faster New Test Method Expected to Generate Revenue in 2023 FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient's sputum sample.
- 08/30/2023
|
Avalon GloboCare announces Laboratory Services MSO's expansion into Arizona
- Avalon GloboCare Corp (NASDAQ:ALBT) told investors that Laboratory Services MSO (LSM), in which it owns a 40% interest, is opening a new laboratory — Veritas Laboratories — in Scottsdale, Arizona. The company noted that Veritas is a CLIA-certified and COLA-accredited laboratory that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing.
- 08/21/2023
|
Avalon's Laboratory Services MSO Announces Expansion into Arizona
- New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023 Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint FREEHOLD, N.J.
- 08/21/2023
|
Avalon GloboCare investee buys Houston-based lab testing facility
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that Laboratory Services MSO, in which the company holds a 40% interest, has acquired DE Laboratory LLC. The Houston-based lab expands LSM's market penetration in Texas and provides a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing, according to a statement.
- 07/24/2023
|
Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
- DE Laboratory in Texas Performs 1,500 Lab Tests Per Month with Focus on Toxicology and Wellness Testing; Expansion Underway DE Laboratory in Texas Performs 1,500 Lab Tests Per Month with Focus on Toxicology and Wellness Testing; Expansion Underway
- 07/24/2023
|
Avalon GloboCare investee LSM inks lab testing deal with GeneX
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned Laboratory Services MSO, LLC (LSM) has signed an exclusive master service agreement (MSA) with GeneX Laboratory Professional Corp to be the exclusive testing provider for toxicology testing, genetic testing, and others. The developer of innovative cell-based technology, cellular therapy and precision diagnostics said GeneX has licenses with major providers such as Aetna California, United Health Care, Cigna (NYSE:CI), and Medicaid in 21 states, offering a range of high-quality testing, including Liquid Chromatography-Mass Spectrometry (LC-MS) drug testing, genetic testing, urinary testing and COVID-19 PCR testing.
- 07/19/2023
|
Avalon GloboCare says 2023 will be ‘pivotal year' as it executes new commercial strategy
- Avalon GloboCare Corp (NASDAQ:ALBT) has updated investors on its progress in implementing its new commercial strategy focused on laboratory acquisitions and diagnostics. In a letter to shareholders, the company's CEO David Jin noted that the company intends to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.
- 07/10/2023
|
Avalon GloboCare highlights the 2022 results of its latest investment, Laboratory Services MSO
- Avalon GloboCare Corp (NASDAQ:ALBT) has announced 2022 financial results for Laboratory Services MSO LLC, a clinical diagnostics and reference laboratory that Avalon acquired a 40% interest earlier this year. LSM saw revenue of $14.7 million and gross profit of $8.1 million, the company said.
- 04/27/2023
|
Avalon GloboCare excited as it closes earnings accretive investment in testing firm
- Avalon GloboCare Corp (NASDAQ:ALBT) has now completed its investment to take a 40% stake in drug testing firm Laboratory Services MSO (LSM). The California based investee, LSM, has a portfolio of testing services including diagnostic tests, drug testing, toxicology, pharmacogenetics, general bloodwork, and other specialist tests.
- 02/13/2023
|
Avalon GloboCare says it has been issued with a US patent for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules
- Avalon GloboCare Corp (NASDAQ:ALBT) has announced that the US Patent and Trademark Office (USPTO) has issued it with US Patent No. 11,555,060, titled 'QTY Fc Fusion Water Soluble Receptor Proteins', which was jointly filed with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
- 01/17/2023
|
Avalon GloboCare appoints Lourdes Felix, CEO of a premier addiction treatment company, to its board
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has appointed entrepreneur and corporate finance executive Lourdes Felix to its board of directors. The Freehold, New Jersey-based biotechnology company noted that Felix has 30 years of combined experience in capital markets, public accounting and in the private sector.
- 01/11/2023
|
Avalon GloboCare reveals deployment of breakthrough fusion gene map technology
- Avalon GloboCare Corp (NASDAQ:ALBT) revealed that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The Freehold, New Jersey-based biotechnology company is enabling the development and commercialization of companion diagnostics and novel therapeutic targets for leukemia patients.
- 01/03/2023
|
Avalon GloboCare raises $4M in Series A preferred stock to fund Laboratory Services MSO acquisition
- Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has raised $4 million through a private placement of shares of its Series A preferred stock with the company's chairman, Daniel Lu. The gross proceeds are in addition to the previously announced private placement of $5 million of Series A preferred stock, all of which will be used to pay a portion of the purchase price for the announced acquisition of Laboratory Services MSO, LLC, Avalon said.
- 12/14/2022
|
